SCHEDULE: Brandes Investment Partners Discloses 19.6% Stake in Grifols SA

Brandes Investment Partners, L.P. has filed an amended Schedule 13G, reporting a 19.6% beneficial ownership in Grifols SA's Common Shares.

Summary

• Brandes Investment Partners, L.P. reported beneficial ownership of 29,126,291.55 American Depositary Receipts (ADRs) and 22,107,370 Ordinary Shares (ORDs) of Grifols SA.
• This combined ownership represents 19.6% of the class of Grifols SA's Common Shares.
• Brandes Investment Partners holds shared dispositive power over these securities, with no sole or shared voting power.
• The investment is certified as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Grifols SA.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive, and long-term investment by a reputable institutional investor, suggesting confidence in the issuer without implying any immediate operational changes or financial distress.

Positives

• A significant institutional investor, Brandes Investment Partners, maintains a substantial stake (19.6%) in Grifols SA, indicating continued confidence.
• The investment is stated to be in the ordinary course of business, not for control purposes, suggesting a passive, long-term investment strategy.

Risks

• No specific risks related to Grifols SA's operations or financial health are disclosed in this ownership filing.

Future Outlook

This filing does not contain forward-looking statements or guidance from Grifols SA, as it is an ownership disclosure by an investor.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant, passive investment by a major institutional investor in Grifols SA, a company known for plasma-derived medicines. Such large stakes by value investors like Brandes can signal long-term confidence in the company's fundamentals within its sector.

Comparison to Industry Standards

• A 19.6% stake is a substantial position for an institutional investor, often indicating a high-conviction investment.
• Brandes Investment Partners is known for its value investing approach, suggesting they see long-term value in Grifols SA, which operates in the global healthcare and plasma-derived therapies market, competing with companies like CSL Behring and Takeda.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like Brandes Investment Partners could be viewed positively, signaling confidence in the company's long-term value.

Next Steps

• Brandes Investment Partners will file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1%).

Key Dates

Recommendation

This Schedule 13G filing indicates that Brandes Investment Partners, a known value investor, maintains a substantial 19.6% stake in Grifols SA. This suggests continued long-term confidence in the company's value proposition. As a passive ownership disclosure, it does not provide new operational or financial performance data to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors, while new investors might consider it a positive signal for further due diligence.

Keywords

Grifols SA, Brandes Investment Partners, Schedule 13G, Beneficial Ownership, Common Shares, ADRs, Institutional Investor, Equity Stake